Publications scientifiques

2602 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2021

JOURNALGynecologie, obstetrique, fertilite & senologie

PREMIER AUTEURMathelin C

TITRE[The HRT follow-up consultation. What to do in case of breast pain. CNGOF and GEMVi clinical practice guidelines].

ANNÉE2021

JOURNALGynecologie, obstetrique, fertilite & senologie

PREMIER AUTEURMathelin C

TITRE[The HRT follow-up consultation. What to do in case of breast tumor (clinical or radiological) and microcalcifications. CNGOF and GEMVi clinical practice guidelines].

ANNÉE2021

JOURNALNature communications

PREMIER AUTEURCoassolo S

TITRECitrullination of pyruvate kinase M2 by PADI1 and PADI3 regulates glycolysis and cancer cell proliferation.

ANNÉE2021

JOURNALCancer research

PREMIER AUTEURFrau C

TITREDeciphering the role of intestinal crypt cell populations in resistance to chemotherapy.

ANNÉE2021

JOURNALScientific reports

PREMIER AUTEURBehtaji S

TITREIdentification of oxytocin-related lncRNAs and assessment of their expression in breast cancer.

ANNÉE2021

JOURNALEuropean journal of medical genetics

PREMIER AUTEURNambot S

TITREIncidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and Impact on patients.

ANNÉE2021

JOURNALClinics and research in hepatology and gastroenterology

PREMIER AUTEURLegoux JL

TITRERenal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.

ANNÉE2021

JOURNALBlood cancer journal

PREMIER AUTEURMshaik R

TITREHSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.

ANNÉE2021

JOURNALClinical nuclear medicine

PREMIER AUTEURSomme F

TITRE18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST.

ANNÉE2021

JOURNALESMO open

PREMIER AUTEURThiery-Vuillemin A

TITREAn analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques